

09/28/2005 WED 13:39 FAX 510 262 7095 Berlex Biosciences

RECEIVED
CENTRAL FAX CENTER

SEP 28 2005

001/012

Berlex Biosciences
Corporate Patents
2600 Hilltop Drive
Richmond, California 94806
(510) 669-4529 WK
(510) 262-7095 FAX



Fax


To:	USPTO, Amendment/Reply	From:	Alishia Rowe-Babb
Fax:	(571) 273-8300	Pages:	12 (includes fax cover page)
Phone:		Dates:	September 28, 2005
Re:		CC:	

Case Docket No.: 51791AUSD1

In re Application of: Harkin et al.
Serial No. 10/616,279
Filing Date: 08, July, 2005

Items Faxed: Transmittal Form and Response to Office Action Amendment/ Reply.

I hereby certify that this paper is being faxed to the office of Amend/Reply at facsimile (571) 273-8300 on September 28, 2005


Alishia L. Rowe-Babb

9-28-05
Date of Signature

09/28/2005 WED 13:39 FAX 510 262 7095 Berlex Biosciences

RECEIVED
CENTRAL FAX CENTER

SEP 28 2005

4002/012

PTO/SB/21 (09-04)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**


(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/616,279
Filing Date	July 08, 2003
First Named Inventor	Harkins et al.
Art Unit	1644
Examiner Name	M. Szperka
Attorney Docket Number	51791AUSD1


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please Identify below):
Remarks This response is to a non final office action dated July 05, 2005, being facsimile transmitted to the USPTO centralized fax number (571)-273-8300		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Berlex Biosciences		
Signature			
Printed name	Wendy L Washtien, Ph.D.		
Date	September 28, 2005	Reg. No.	36,301

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Alishia Rowe-Babb	Date	September 28, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

09/28/2005 WED 13:39 FAX 510 262 7095 Berlex Biosciences

RECEIVED
CENTRAL FAX CENTER

003/012

SEP 28 2005

10/616,279

Case 51791AUSD1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

:

Harkins et al.

:

Serial No. 10/616,279

:

Group Art Unit: 1644

Filed July 8, 2003

:

Examiner : M. Szperka

For DNA ENCODING A NOVEL RG1 POLYPEPTIDE

**Mail Stop Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450**

Sir:

AMENDMENT

This amendment is in response to the Office Action, mailed July 5, 2005, in which a three month period was set for response.

Amendments to the Specification are found on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 8 of this paper.

51791AUSD1amnd